Skip to content

Study for a new eradication therapy of penicillin-allergic patients with helicobacter pylori infection

Study for a new eradication therapy of penicillin-allergic patients with helicobacter pylori infection

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023702
Enrollment
Unknown
Registered
2019-06-08
Start date
2019-06-17
Completion date
Unknown
Last updated
2019-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Group 1:quadruple therapy containing cefuroxime and minocycline
Group 2:quadruple therapy containing cefuroxime and metronidazole
Group 3:quadruple therapy containing minocycline and metronidazole

Sponsors

Department of Gastroenterology, Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Consecutive patients with dyspepsia who are referred to the Peking University Third Hospital; 2. Urea breath test positive or gastroscopic mucosal biopsy revealed double positive staining of Hp RUT and Warthin-Starry; 3. Aged 18 years and elder man or woman; 4. penicillin allergy; 5. Willing and available for participation this study.

Exclusion criteria

Exclusion criteria: 1. Received treatment for Hp infection; Taking any drug which could influence the study results such as PPI, H2-receptor blockers, bismuth salts and antibiotics in the previous 4 weeks; 2. Gastrointestinal malignancy; 3. Zollinger-Ellison syndrome; 4. Previous gastric and esophageal surgeries; 5. Severe concomitant cardiovascular, respiratory, renal, hepatic, hematological, neurological, endocrine or psychiatric diseases; 6. History of allergy to any of the drugs used in the study; 7. Pregnancy or lactation; 8. Any other clinically significant medical condition that could increase risk of side effects.

Design outcomes

Primary

MeasureTime frame
Eradication rate;

Secondary

MeasureTime frame
Compliance;safety;

Countries

China

Contacts

Public ContactLiya ZHOU

Peking University Third Hospital

zhoumed@126.com+86 15611908239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026